Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines

BACKGROUND: New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Di, Huang, Yu, Huang, Zisheng, Weng, Jiefeng, Zhang, Shuai, Gu, Weili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582545/
https://www.ncbi.nlm.nih.gov/pubmed/31244554
http://dx.doi.org/10.1186/s12935-019-0885-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582545/
https://www.ncbi.nlm.nih.gov/pubmed/31244554
http://dx.doi.org/10.1186/s12935-019-0885-z

Ejemplares similares